▪ Committed to sustainable growth and long-term planning
▪ Dedicated to making investments to support increased customer demand
▪ Maintain efficiency and quality in development and manufacturing processes
Ravensburg, Germany: Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announces additional investments as part of its long-term dedication to customer partnerships. Vetter’s extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development. The pharmaceutical service provider plans with future-driven considerations to meet its long-lead goals for continued expansion and customer satisfaction.
Vetter is investing 230 million euros in its new production building, which is currently under construction at the global corporate headquarters site in Ravensburg, Germany. The company recently reached a significant milestone in the construction process, as the shell of the building is now complete, following the start of construction in November 2021. The building is 122m long, 44m wide and 32m tall and will feature several new commercial filling lines to effectively increase aseptic manufacturing capacity for its global customer base. Vetter plans to install the first cleanrooms by the end of 2024.
According to Vetter Managing Director Thomas Otto, “Our new production building signifies our ongoing dedication to support the needs of our customers concerning their complex injectable drug products with regards to packaging systems, specific process requirements and batch sizes. This is just one of several investments we are currently undertaking to manage our sustainable growth.”
Further investments include the increase of lab space for analytical services, the expansion of filling capacity through new commercial production lines at other sites in the EU, the expansion in cool storage and warehousing, as well as a new technical equipment warehouse. Added to this are the optimization of infrastructure at all global sites to further develop processes, the development of new compounding and preparation rooms, and as a result, the optimization of the handling incoming and outgoing products.
“In our industry, the needs of our customers and the patients they serve continue to evolve,” emphasizes Vetter Managing Director Peter Soelkner. “Our job as a leading CDMO is to act as a strong partner, take the proactive steps necessary to identify relevant industry trends, and thus, to meet the evolving demands of the market through offering adequate resources. Over the coming years, we will continue to make further investments to stay on track with this commitment that we have made as a service provider, from the early development phase to aseptic fill and finish through assembly and packaging services.”
Find the Vetter press kit and more background information here.
Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com
